RestoreSensor Implantable Neurostimulators 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Medtronic 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2016-04-29
  • 사례 출판 날짜
    2016-04-29
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Medical Device Safety Alert
  • 원인
    Medical device safety alert: medtronic restoresensor implantable neurostimulators medical device manufacturer, medtronic, has issued a medical device safety alert concerning its restoresensor multi-program rechargeable neurostimulator and medtronic restoresensor surescan mri [product codes: 37714 and 97714] the manufacturer has confirmed four instances of loss of therapy during recharging of a restoresensor implantable neurostimulator, for a rate of 0.007% of devices distributed worldwide. by design, stimulation therapy turns off when battery voltage depletes below 3.575 volts. in the reported occurrences, a charging session was terminated prior to obtaining a recharge threshold voltage of 3.615, which triggered a rapid battery depletion state. as a result of the rapid battery discharge state, the implanted neurostimulators depleted to 1.925 volts (a state of overdischarge) in one to two days rather than the typical 30 days. according to the manufacturer, insufficient coupling (charging efficiency) between the recharger and the implanted neurostimulator during the recharge session was found to be a key factor in the reported events. once a device is in the over discharge state, therapy is interrupted with return of patient symptoms and can only be restored using the physician recharge mode of the recharger. as described in labeling, if three occurrences of overdischarge occur, the neurostimulator will trigger end of life, and must be replaced to restore therapy. affected users are advised to follow current recharge instructions, paying particular attention to charging efficiency and battery charge level indicators on the recharger. check the neurostimulator battery charge level once a day or more frequently as needed. keep the neurostimulator sufficiently charged to maintain therapy. it can be charged at any time; do not need to wait for a low battery message. during neurostimulator recharging, monitor the charging efficiency row and adjust the antenna to obtain as many solid black boxes as possible. if only two boxes are filled in (6 or more boxes are empty) adjust the antenna to improve the signal strength between the neurostimulator and recharger. during recharging, ensure the neurostimulator battery charge level is at least 25% before ending the charge session. however, a full battery charge is ideal. according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 29 april 2016.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Medical Device Safety Alert: Medtronic RestoreSensor Implantable Neurostimulators
  • Manufacturer

Manufacturer

  • 제조사 모회사 (2017)
  • 제조사 의견
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    DH